Insight Molecular Diagnostics Q3 2026 Results: Net Loss of $3.58M, Loss Narrows
Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.
- Key figure
- Net loss $3.58M